Chiasma midpoint value $375 MUSD

Chiasma, a late-stage biotech developing an oral drug candidate for acromegaly, plans to raise $75 million by offering 5.36 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Chiasma would trade at a market value of $375 million.